

Resource Summary Report

Generated by [RRID](#) on Aug 13, 2026

DNMT3A (D23G1) XP(tm) Rabbit mAb

RRID:AB_2277449

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3598, RRID:AB_2277449

Antibody Information

URL: http://antibodyregistry.org/AB_2277449

Proper Citation: Cell Signaling Technology Cat# 3598, RRID:AB_2277449

Target Antigen: Dnmt3a

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P

Antibody Name: DNMT3A (D23G1) XP(tm) Rabbit mAb

Description: This monoclonal targets Dnmt3a

Target Organism: rat, cow, mouse, human

Antibody ID: AB_2277449

Vendor: Cell Signaling Technology

Catalog Number: 3598

Record Creation Time: 20250819T213624+0000

Record Last Update: 20250819T233024+0000

Ratings and Alerts

No rating or validation information has been found for DNMT3A (D23G1) XP(tm) Rabbit mAb.

No alerts have been found for DNMT3A (D23G1) XP(tm) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Perkins B, et al. (2026) Dnmt3a-dependent de novo DNA methylation enforces lineage commitment and preserves functionality of memory Th1 and Tfh cells. *Cell reports*, 45(3), 117062.

Pathak M, et al. (2026) Mouse germline cysts contain a fusome-like structure that mediates oocyte development. *eLife*, 14.

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD⁺ to eradicate KRAS-driven AML. *Cell metabolism*, 38(6), 1113.

Lewis AC, et al. (2026) Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia. *Cell*, 189(1), 215.

Le BV, et al. (2026) Pol?? activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia. *Cell reports. Medicine*, 7(3), 102687.

Kageyama I, et al. (2026) Neural stem cells as potential mediators of prenatal dietary stress through epigenetic mechanisms. *Stem cell reports*, 21(7), 102996.

Bayraktar E, et al. (2025) Epigenetic modulation of BARD1 to enhance anti-VEGF therapy. *Cell reports. Medicine*, 6(9), 102329.

Huang X, et al. (2024) ZFP281 controls transcriptional and epigenetic changes promoting mouse pluripotent state transitions via DNMT3 and TET1. *Developmental cell*, 59(4), 465.

Akhter MZ, et al. (2024) FAK regulates tension transmission to the nucleus and endothelial transcriptome independent of kinase activity. *Cell reports*, 43(6), 114297.

Constantinou M, et al. (2024) Lineage specification in glioblastoma is regulated by METTL7B. *Cell reports*, 43(6), 114309.

Fernandes V, et al. (2023) Neuroepigenetic Changes in DNA Methylation Affecting Diabetes-Induced Cognitive Impairment. *Cellular and molecular neurobiology*, 43(5), 2005.

Chen W, et al. (2021) Fetal growth restriction impairs hippocampal neurogenesis and cognition via Tet1 in offspring. *Cell reports*, 37(5), 109912.

Sin-Chan P, et al. (2019) A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. *Cancer cell*, 36(1), 51.

Bagheri-Fam S, et al. (2017) Testis Determination Requires a Specific FGFR2 Isoform to Repress FOXL2. *Endocrinology*, 158(11), 3832.